FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2554477172> ?p ?o ?g. }

• W2554477172 endingPage "189" @default.
• W2554477172 startingPage "182" @default.
• W2554477172 abstract "Rationale: OT329 SOLIS is a generic candidate for the branded asthma treatment, ADVAIR DISKUS (fluticasone propionate/salmeterol xinafoate), and, as such, the manufacturer is required to provide evidence of clinical “bioequivalence” as a condition for regulatory approval.Objectives: The objective of the current study was to determine if SOLIS and DISKUS provided bioequivalent improvements in lung function at two time points: Day 1 and Week 4.Methods: This study was a randomized, multiple-dose, placebo-controlled, parallel-group design conducted in the United States (NCT02260492) with a 2-week run-in followed by a 4-week treatment period. Consenting patients were randomized to treatment with OT329 SOLIS 100/50, ADVAIR DISKUS 100/50, or placebo. Lung function was measured predose and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hours after the first dose to test equivalence of the β-agonist salmeterol component based on FEV1 area under the curve (0–12 h). After 4 weeks of twice-daily dosing, trough (predose) FEV1 was measured to evaluate equivalence of the fluticasone propionate corticosteroid component. Bioequivalence was concluded if the 90% confidence interval (CI) for the ratio of the products fell within 80–125%.Measurements and Main Results: Of the 1,524 screened, 879 patients with asthma were randomized to treatment (n = 418 SOLIS, 419 DISKUS, 42 placebo). OT329 SOLIS and ADVAIR DISKUS were bioequivalent at Day 1, with an FEV1 area under the curve (0–12 h) test/reference ratio of 108% (90% CI = 94–122%). Likewise, the products were bioequivalent at Week 4 with a trough FEV1 test/reference ratio of 105% (90% CI = 90–119). Both active treatments were superior to placebo (P < 0.05) at both time points.Conclusions: The data support a conclusion of clinical bioequivalence of OT329 SOLIS to ADVAIR DISKUS.Clinical trial registered with www.clinicaltrials.gov (NCT02260492)." @default.
• W2554477172 created "2016-11-30" @default.
• W2554477172 creator A5080552653 @default.
• W2554477172 creator A5084848572 @default.
• W2554477172 creator A5085704505 @default.
• W2554477172 date "2017-02-01" @default.
• W2554477172 modified "2023-09-26" @default.
• W2554477172 title "Clinical Bioequivalence of OT329 SOLIS and ADVAIR DISKUS in Adults with Asthma" @default.
• W2554477172 cites W2010810014 @default.
• W2554477172 cites W2027285152 @default.
• W2554477172 cites W2063045365 @default.
• W2554477172 cites W2083765816 @default.
• W2554477172 cites W2108678383 @default.
• W2554477172 cites W2125078269 @default.
• W2554477172 doi "https://doi.org/10.1513/annalsats.201606-436oc" @default.
• W2554477172 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27849125" @default.
• W2554477172 hasPublicationYear "2017" @default.
• W2554477172 type Work @default.
• W2554477172 sameAs 2554477172 @default.
• W2554477172 citedByCount "2" @default.
• W2554477172 countsByYear W25544771722017 @default.
• W2554477172 countsByYear W25544771722022 @default.
• W2554477172 crossrefType "journal-article" @default.
• W2554477172 hasAuthorship W2554477172A5080552653 @default.
• W2554477172 hasAuthorship W2554477172A5084848572 @default.
• W2554477172 hasAuthorship W2554477172A5085704505 @default.
• W2554477172 hasConcept C112705442 @default.
• W2554477172 hasConcept C126322002 @default.
• W2554477172 hasConcept C142724271 @default.
• W2554477172 hasConcept C204787440 @default.
• W2554477172 hasConcept C27081682 @default.
• W2554477172 hasConcept C2776042228 @default.
• W2554477172 hasConcept C2776719499 @default.
• W2554477172 hasConcept C2779028295 @default.
• W2554477172 hasConcept C2781018748 @default.
• W2554477172 hasConcept C2781212218 @default.
• W2554477172 hasConcept C42219234 @default.
• W2554477172 hasConcept C42404028 @default.
• W2554477172 hasConcept C44249647 @default.
• W2554477172 hasConcept C71924100 @default.
• W2554477172 hasConceptScore W2554477172C112705442 @default.
• W2554477172 hasConceptScore W2554477172C126322002 @default.
• W2554477172 hasConceptScore W2554477172C142724271 @default.
• W2554477172 hasConceptScore W2554477172C204787440 @default.
• W2554477172 hasConceptScore W2554477172C27081682 @default.
• W2554477172 hasConceptScore W2554477172C2776042228 @default.
• W2554477172 hasConceptScore W2554477172C2776719499 @default.
• W2554477172 hasConceptScore W2554477172C2779028295 @default.
• W2554477172 hasConceptScore W2554477172C2781018748 @default.
• W2554477172 hasConceptScore W2554477172C2781212218 @default.
• W2554477172 hasConceptScore W2554477172C42219234 @default.
• W2554477172 hasConceptScore W2554477172C42404028 @default.
• W2554477172 hasConceptScore W2554477172C44249647 @default.
• W2554477172 hasConceptScore W2554477172C71924100 @default.
• W2554477172 hasIssue "2" @default.
• W2554477172 hasLocation W25544771721 @default.
• W2554477172 hasLocation W25544771722 @default.
• W2554477172 hasOpenAccess W2554477172 @default.
• W2554477172 hasPrimaryLocation W25544771721 @default.
• W2554477172 hasRelatedWork W131230462 @default.
• W2554477172 hasRelatedWork W1995379743 @default.
• W2554477172 hasRelatedWork W2074519860 @default.
• W2554477172 hasRelatedWork W2134478384 @default.
• W2554477172 hasRelatedWork W2554477172 @default.
• W2554477172 hasRelatedWork W2767618211 @default.
• W2554477172 hasRelatedWork W2789391026 @default.
• W2554477172 hasRelatedWork W2965511266 @default.
• W2554477172 hasRelatedWork W2984327395 @default.
• W2554477172 hasRelatedWork W3138310799 @default.
• W2554477172 hasVolume "14" @default.
• W2554477172 isParatext "false" @default.
• W2554477172 isRetracted "false" @default.
• W2554477172 magId "2554477172" @default.
• W2554477172 workType "article" @default.